title: Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature.
abstract: Half of all men with prolactin (PRL)-producing macroadenomas present with hypogonadism, decreased libido and impotence, and therefore require testosterone replacement. However, very little is known about the effect of testosterone on prolactinomas. We report a case of an 18-year-old obese man who presented with hypogonadism and hyperprolactinaemia and underwent a transphenoidal hypophysectomy after a computer tomography scan showed the presence of a suprasellar macroadenoma. On separate occasions, we documented a rise in PRL when testosterone replacement was started and a fall in PRL when testosterone replacement was stopped (r = 0.6090, P = 0.0095). Furthermore, imaging studies suggested the possibility of tumour re-growth after testosterone therapy. We hypothesize that the exogenous testosterone was aromatized to oestradiol, which stimulated the release of PRL by the anterior pituitary. This was supported by the increase in oestradiol levels after testosterone replacement, although statistical significance was not achieved due to the availability of only a few data points. This case highlights the need to be aware of testosterone-replacement-induced hyperprolactinaemia, an under-recognized complication of androgen replacement in this setting. The use of aromatase inhibitors together with testosterone-replacement therapy or the use of non-aromatizable androgens might be indicated in such patients. Taken together, this report and previous studies show that dopamine agonists apparently do not suppress the hyperprolactinaemia induced by testosterone replacement.
authors.affiliation: Department of Clinical Biochemistry, Royal Liverpool & Broadgreen University Hospital, Liverpool L7 8XP, UK. ravsodi@yahoo.com
authors.forename: R
authors.initials: R
authors.lastname: Sodi
authors.forename: R
authors.initials: R
authors.lastname: Fikri
authors.forename: M
authors.initials: M
authors.lastname: Diver
authors.forename: L
authors.initials: L
authors.lastname: Ranganath
authors.forename: J
authors.initials: J
authors.lastname: Vora
mesh_terms: D000236:Adenoma / Q000150:complications* / Q000601:surgery; D000293:Adolescent; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced*; D007006:Hypogonadism / Q000628:therapy; D007016:Hypophysectomy; D008297:Male; D009765:Obesity / Q000150:complications; D010911:Pituitary Neoplasms / Q000150:complications* / Q000601:surgery; D013739:Testosterone / Q000009:adverse effects* / Q000097:blood
chemical_list: D047072:Aromatase Inhibitors; D018491:Dopamine Agonists; D013739:Testosterone; D004958:Estradiol